Patient factors and their impact on neutropenic events: a systematic review and meta-analysis
Open Access
- 16 April 2019
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 27 (7) , 2413-2424
Abstract
Neutropenia is associated with an increased risk of mortality and hospitalisation. Strategies, including the prescribing of colony-stimulating growth factors (CSFs), are adopted when a high risk (> 20%) of neutropenic complications are seen in the clinical trial setting. With a diverse treatment population that may differ from the patient groups recruited to studies, appropriate prescribing decisions by clinicians are essential. At present, results are conflicting from studies evaluating the risks of certain patient attributes on neutropenic events; we aimed to aggregate these associations to guide future management.Keywords
Funding Information
- National Insitute for Health Research (DRF 2017-10-016)
This publication has 53 references indexed in Scilit:
- Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: A clinical auditClinical Neurology and Neurosurgery, 2013
- Real-World Impact of Granulocyte-Colony Stimulating Factor on Febrile NeutropeniaCurrent Oncology, 2013
- Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN ClassifierAdvances in Bioinformatics, 2011
- Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapyCancer, 2010
- Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancerSupportive Care in Cancer, 2010
- Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumoursEuropean Journal of Cancer Care, 2010
- Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia StudyBritish Journal of Haematology, 2009
- Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatmentSupportive Care in Cancer, 2006
- Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile NeutropeniaSupportive Cancer Therapy, 2005
- Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapyBreast Cancer Research and Treatment, 2005